MIF4GD抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain tissue using P01063(GSTA2 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human lung cancer tissue using P01063(GSTA2 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

MIF4GD antibody targets macrophage migration inhibitory factor (MIF), a multifunctional cytokine involved in inflammation, immune regulation, and cancer progression. MIF is secreted by immune cells, endothelial cells, and tumor-associated cells, acting through receptors like CD74 and CXCRs to activate downstream signaling pathways (e.g., MAPK, PI3K/Akt). It promotes pro-inflammatory responses, cell proliferation, and angiogenesis while inhibiting apoptosis. Dysregulated MIF expression is linked to autoimmune diseases (e.g., rheumatoid arthritis), sepsis, and cancers, making it a therapeutic target.

The MIF4GD antibody specifically recognizes an epitope within the MIF protein, often used to neutralize its activity or detect expression in research. Studies utilize this antibody to investigate MIF's role in disease mechanisms, evaluate its inhibition in preclinical models, or validate diagnostic biomarkers. Its application spans immunoblotting, immunohistochemistry, and functional assays to block MIF-CD74 interactions. Recent research explores MIF4GD's potential in combination therapies, particularly in cancers where MIF-driven pathways confer resistance to conventional treatments. As MIF inhibitors advance into clinical trials, this antibody remains a critical tool for elucidating MIF's complex biology and therapeutic targeting.